269 related articles for article (PubMed ID: 31397840)
1. Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
Hollan I; Ronda N; Dessein P; Agewall S; Karpouzas G; Tamargo J; Niessner A; Savarese G; Rosano G; Kaski JC; Wassmann S; Meroni PL
Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):104-114. PubMed ID: 31397840
[TBL] [Abstract][Full Text] [Related]
2. Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up.
Tournadre A; Pereira B; Dubost JJ; Rincheval N; Rat AC; Combe B; Soubrier M
Clin Exp Rheumatol; 2017; 35(2):296-302. PubMed ID: 28079508
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Risk Assessment and Therapeutic Implications in Rheumatoid Arthritis.
Halacoglu J; Shea LA
J Cardiovasc Transl Res; 2020 Oct; 13(5):878-890. PubMed ID: 32080804
[TBL] [Abstract][Full Text] [Related]
4. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.
Curtis JR; John A; Baser O
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1282-91. PubMed ID: 22504829
[TBL] [Abstract][Full Text] [Related]
5. Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis?
Danninger K; Hoppe UC; Pieringer H
Int J Rheum Dis; 2014 Jul; 17(6):606-11. PubMed ID: 24931356
[TBL] [Abstract][Full Text] [Related]
6. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.
Naerr GW; Rein P; Saely CH; Drexel H
Vascul Pharmacol; 2016 Jun; 81():22-30. PubMed ID: 26903239
[TBL] [Abstract][Full Text] [Related]
7. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
; ;
Atherosclerosis; 2019 Nov; 290():140-205. PubMed ID: 31591002
[No Abstract] [Full Text] [Related]
8. News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published.
Stock J
Atherosclerosis; 2019 Dec; 291():124-126. PubMed ID: 31668350
[No Abstract] [Full Text] [Related]
9. Atherogenic lipid profiles and its management in patients with rheumatoid arthritis.
Nurmohamed MT
Vasc Health Risk Manag; 2007; 3(6):845-52. PubMed ID: 18200805
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of lipid phenotypes, serum lipid behaviour over follow-up and predictors of serum lipid levels in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease-modifying anti-rheumatic drugs.
Sánchez T; Contreras-Yáñez I; Elías-López D; Aguilar Salinas CA; Pascual-Ramos V
Clin Exp Rheumatol; 2014; 32(4):509-15. PubMed ID: 25005131
[TBL] [Abstract][Full Text] [Related]
11. Lipids and lipid changes with synthetic and biologic disease-modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk.
Myasoedova E
Curr Opin Rheumatol; 2017 May; 29(3):277-284. PubMed ID: 28207495
[TBL] [Abstract][Full Text] [Related]
12. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm.
Robertson J; Peters MJ; McInnes IB; Sattar N
Nat Rev Rheumatol; 2013 Sep; 9(9):513-23. PubMed ID: 23774906
[TBL] [Abstract][Full Text] [Related]
13. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors.
Toms TE; Symmons DP; Kitas GD
Curr Vasc Pharmacol; 2010 May; 8(3):301-26. PubMed ID: 19758115
[TBL] [Abstract][Full Text] [Related]
14. Management of lipid variables in primary cardiovascular prevention: A position paper from the Heart, Vessels and Metabolism Group of the French Society of Cardiology.
Diévart F; Bruckert E; Aboyans V; Bekka S; Boccara F; Bourdon Baron Munoz B; Emmerich J; Farnier M; Gallo A; Lemesle G; Paillard F; Schiele F; Kownator S;
Arch Cardiovasc Dis; 2024 May; 117(5):358-378. PubMed ID: 38762344
[TBL] [Abstract][Full Text] [Related]
15. Hypolipidemic drugs in elderly subjects: Indications and limits.
Gazzola K; Vigna GB
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1064-1070. PubMed ID: 27522161
[TBL] [Abstract][Full Text] [Related]
16. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease.
Myasoedova E; Crowson CS; Kremers HM; Roger VL; Fitz-Gibbon PD; Therneau TM; Gabriel SE
Ann Rheum Dis; 2011 Mar; 70(3):482-7. PubMed ID: 21216812
[TBL] [Abstract][Full Text] [Related]
17. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
[TBL] [Abstract][Full Text] [Related]
18. Clinical controversies in lipid management.
Tziomalos K
Panminerva Med; 2015 Jun; 57(2):65-70. PubMed ID: 25669164
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of Nutraceuticals with Lipid Lowering Properties.
Poli A; Visioli F
High Blood Press Cardiovasc Prev; 2019 Apr; 26(2):113-118. PubMed ID: 30877602
[TBL] [Abstract][Full Text] [Related]
20. Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis.
McCarey D; Sturrock RD
Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S124-6. PubMed ID: 19822058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
